A 2 year extension to a 1 year multicenter, randomized, open label, parallel group study of the safety, tolerability and efficacy of two doses (1.5 and 3 mg/day) of everolimus (RAD001) with basiliximab, corticosteroids and optimized administration of cyclosporine in de novo renal transplant recipients.

Trial Profile

A 2 year extension to a 1 year multicenter, randomized, open label, parallel group study of the safety, tolerability and efficacy of two doses (1.5 and 3 mg/day) of everolimus (RAD001) with basiliximab, corticosteroids and optimized administration of cyclosporine in de novo renal transplant recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs Basiliximab; Ciclosporin; Corticosteroids; Everolimus
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Nov 2011 Actual end date (August 2005) added as reported by ClinicalTrials.gov.
    • 04 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top